Publications by authors named "M M Riwes"
Introduction: Lymphodepleting chemotherapy (LDC) is critical to CAR T-cell expansion and efficacy. Despite this, there is not a consensus in the literature regarding the optimal LDC regimen, including dose and frequency.
Methods: We retrospectively reviewed consecutive patients at a single institution that received LDC prior to treatment with the CD19 directed CAR T-cell products axicabtagene ciloleucel and tisagenlecleucel.
Article Synopsis
- Hematopoietic stem cell transplantation (HSCT) can lead to various cardiovascular complications, and this study aimed to assess the occurrence and risk factors of these events in patients post-transplant.
- Researchers analyzed data from 3,354 adult patients who underwent HSCT from 2008 to 2019, tracking cardiovascular outcomes within 100 days and beyond, with a focus on incidents like heart failure and atrial fibrillation.
- Results showed a low short-term incidence of cardiovascular events (4.1%) but a higher long-term incidence (13.9%), particularly among allogeneic transplant recipients and individuals with pre-existing heart conditions.
Article Synopsis
- A study aimed to create a risk score for assessing cardiovascular risks in patients undergoing hematopoietic stem cell transplantation (HSCT) due to limited existing guidelines.
- Using data from the CARE-BMT study, researchers analyzed various predictive factors related to cardiovascular events in over 2,400 HSCT patients, leading to the development of a point-based risk score.
- This score categorizes patients into low, intermediate, and high-risk groups for cardiovascular issues post-transplant, potentially aiding in specialist referrals and long-term monitoring of high-risk individuals.
Article Synopsis
- - The study explored the feasibility of using resistant potato starch (RPS) in 10 adults undergoing allogeneic hematopoietic stem cell transplantation (HCT) to evaluate its impact on gut microbiota and metabolites.
- - Results showed that RPS increased fecal levels of butyrate significantly compared to when participants were not on RPS, achieving the target adherence of over 70% in the treatment group.
- - Additionally, while plasma metabolites changed over time, those in RPS recipients were more stable than historical controls, indicating potential benefits of RPS in HCT patients, leading to a planned phase 2 trial on its effects on graft-versus-host disease.
Patients who undergo human leukocyte antigen-matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative conditioning for hematologic malignancies often develop acute graft-versus-host disease (GVHD) despite standard calcineurin inhibitor-based prophylaxis in combination with methotrexate. This trial evaluated a novel human CD24 fusion protein (CD24Fc/MK-7110) that selectively targets and mitigates inflammation due to damage-associated molecular patterns underlying acute GVHD while preserving protective immunity after myeloablative conditioning. This phase 2a, multicenter study evaluated the pharmacokinetics, safety, and efficacy of CD24Fc in combination with tacrolimus and methotrexate in preventing acute GVHD in adults undergoing MUD HSCT for hematologic malignancies.
View Article and Find Full Text PDF